VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 3
- 主要终点
- To evaluate the safety and tolerability of four vaccination regimens with ZIKV DNA vaccine (VRC-ZKADNA085-00-VP) administered IM at 4 mg.
研究概览
简要总结
Background:
The Zika virus is passed to humans by infected mosquitos. It usually causes fever, rash, joint pain, and red eyes. Recently, some cases of microcephaly (abnormally small head) were reported in babies born to mothers infected with the Zika virus. Rare cases of a severe nerve weakness called Guillain-Barr(SqrRoot)(Copyright) syndrome were reported in some people with Zika virus infection. There is currently no cure for or vaccine against the infection. VRC-ZKADNA085-00-VP is a new vaccine that instructs the body to make a small amount of Zika virus protein. The body may use this to build an immune response.
Objective:
To see if VRC-ZKADNA085-00-VP is safe and causes any side effects.
Eligibility:
Healthy people ages 18 35
Design:
Participants will be screened through a separate protocol with:
- Medical history
- Physical exam
- Lab and urine tests
Participants will be randomly assigned to 1 of 4 study groups. They will have about 18 clinic visits over 2 years. Most will occur in the first year, with long-term follow-up visits at months 18 and 24. Visits include a physical exam and blood and urine tests.
Participants will have vaccine injections. A high-pressure device pushes the vaccine through the skin and into the muscle of the upper arm. They will have 2-3 injections depending on their group.
Vaccine visits last 4-6 hours. Others last 1-2 hours.
Participants will keep a diary for 7 days after each injection. They will record their temperature and measure any skin changes at the injection site each day.
Participants might have extra visits and blood tests if they have health changes.
详细描述
Study Design:
This is a Phase I/Ib, randomized, multicenter clinical study to evaluate the safety, tolerability, and immunogenicity of four vaccination regimens against Zika virus (ZIKV) disease. Vaccination regimens with the VRC-ZKADNA085-00-VP (ZIKV DNA) vaccine administered on Day 0 and Week 8 (Group 1); on Day 0 and Week 12 (Group 2); on Day 0, Weeks 4 and 8 (Group 3); and on Day 0, Weeks 4 and 20 (Group 4) will be tested. The primary hypothesis is that the ZIKV DNA vaccine will be safe and well tolerated in healthy adults. A secondary hypothesis is that all vaccine regimens will elicit a ZIKV-specific immune response. The primary objectives are to evaluate the safety and tolerability of the investigational vaccine regimens in healthy adults. Secondary objectives are related to the immunogenicity of the vaccination regimens.
Product Description:
The investigational VRC-ZKADNA085-00-VP vaccine was developed by the Vaccine Research Center (VRC), NIAID, and is composed of a single closed-circular DNA plasmid that encodes the wild type precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV. Vaccine is supplied in single dose vials at a concentration of 4 mg/mL. ZIKV DNA vaccine dose will be 4 mg administered as an intramuscular (IM) injection in the deltoid muscle.
Subjects:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA:
- •18 to 35 years old
- •Available for clinic visits for 24 months after enrollment
- •Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process
- •Able and willing to complete the informed consent process
- •Willing to donate blood for sample storage to be used for future research
- •In good general health without clinically significant medical history
- •Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) less than or equal to 40 within the 56 days prior to enrollment
- •Agrees not to receive licensed or investigational flavivirus vaccines through 4 weeks after last study injection
- •INCLUSION CRITERIA - LABORATORY CRITERIA WITHIN 56 DAYS PRIOR TO ENROLLMENT:
- •Hemoglobin within institutional normal limits or accompanied by the site PI or designee approval
- •WBC and differential either within institutional normal range or accompanied by site PI or designee approval
- •Total lymphocyte count greater than or equal to 800 cells/mm^3
- •Platelets = 125,000 - 500,000/mm^3
- •Alanine aminotransferase (ALT) less than or equal to 1.25 x institutional upper limit of normal (ULN)
- •Serum creatinine less than or equal to 1.1 x institutional ULN
- •Negative for HIV infection by an FDA approved method of detection
- •INCLUSION CRITERIA - CRITERIA APPLICABLE TO WOMEN OF CHILDBEARING POTENTIAL:
- •Negative human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on day of enrollment
- •Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 12 weeks after the last study vaccination
排除标准
- •FEMALE-SPECIFIC:
- •Breast-feeding or planning to become pregnant while participating through 12 weeks after the last study vaccination
- •EXCLUSION CRITERIA - SUBJECT HAS RECEIVED ANY OF THE FOLLOWING:
- •More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment
- •Blood products within 16 weeks prior to enrollment
- •Inactivated vaccines within 2 weeks prior to enrollment
- •Live attenuated vaccines within 4 weeks prior to enrollment
- •Investigational research products within 4 weeks prior to enrollment or planning to receive investigational products while on the study
- •Current allergen immunotherapy with antigen injections, unless on maintenance schedule
- •Current anti-TB prophylaxis or therapy
- •EXCLUSION CRITERIA - SUBJECT HAS A HISTORY OF ANY OF THE FOLLOWING CLINICALLY SIGNIFICANT CONDITIONS:
- •Laboratory confirmed ZIKV infection by self-report
- •Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the site investigator
- •Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema
- •Asthma that is not well controlled
- •Diabetes mellitus (type I or II), with the exception of gestational diabetes
- •Evidence of autoimmune disease or immunodeficiency
- •Idiopathic urticaria within the past year
- •Hypertension that is not well controlled
- •Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- •Malignancy that is active or history of malignancy that is likely to recur during the period of the study
- •Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years
- •Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen
- •Guillain-Barre Syndrome, Bell s palsy or similar neurological conditions
- •Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within 5 years prior to enrollment, a history of suicide plan or attempt
- •Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent
研究组 & 干预措施
Group 4
ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0,Week 4 and Week 20.
干预措施: VRC-ZKADNA085-00-VP (Biological)
Group 3
ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0, Week 4 and Week 8.
干预措施: VRC-ZKADNA085-00-VP (Biological)
Group 2
ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 12.
干预措施: VRC-ZKADNA085-00-VP (Biological)
Group 1
ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 8.
干预措施: VRC-ZKADNA085-00-VP (Biological)
结局指标
主要结局
To evaluate the safety and tolerability of four vaccination regimens with ZIKV DNA vaccine (VRC-ZKADNA085-00-VP) administered IM at 4 mg.
时间窗: Through 44 weeks of study participation
次要结局
- To evaluate the magnitude and frequency of ZIKV-specific antibodyresponse as measured by neutralization assay.(Four weeks after the second and third injections for each regimen.)